Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 4(2)

Phase 2(1)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04561219Phase 2Completed

Nitazoxanide Therapy for Patients With COVID-19 Pneumonia

Role: collaborator

NCT04256096Phase 3Unknown

Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window

Role: collaborator

NCT03649295Not ApplicableCompleted

Combined Conventional Speech Therapy and Functional Electrical Stimulation in Dysphagia Following Stroke

Role: lead

NCT03088280Phase 4Unknown

Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen

Role: lead

NCT01174524Phase 4Completed

Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme

Role: lead

All 5 trials loaded